161 related articles for article (PubMed ID: 18386787)
1. FGF-8 is involved in bone metastasis of prostate cancer.
Valta MP; Tuomela J; Bjartell A; Valve E; Väänänen HK; Härkönen P
Int J Cancer; 2008 Jul; 123(1):22-31. PubMed ID: 18386787
[TBL] [Abstract][Full Text] [Related]
2. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
4. Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8.
Valta MP; Hentunen T; Qu Q; Valve EM; Harjula A; Seppänen JA; Väänänen HK; Härkönen PL
Endocrinology; 2006 May; 147(5):2171-82. PubMed ID: 16439448
[TBL] [Abstract][Full Text] [Related]
5. An in vivo model of prostate carcinoma growth and invasion in bone.
Fisher JL; Schmitt JF; Howard ML; Mackie PS; Choong PF; Risbridger GP
Cell Tissue Res; 2002 Mar; 307(3):337-45. PubMed ID: 11904770
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of CRMP4, a new prostate cancer metastasis suppressor gene, inhibits tumor growth in a nude mouse intratibial injection model.
Zhou W; Xie P; Pang M; Yang B; Fang Y; Shu T; Liu C; Wang X; Zhang L; Li S; Rong L
Int J Oncol; 2015 Jan; 46(1):290-8. PubMed ID: 25338524
[TBL] [Abstract][Full Text] [Related]
7. FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer.
Valta MP; Tuomela J; Vuorikoski H; Loponen N; Väänänen RM; Pettersson K; Väänänen HK; Härkönen PL
J Cell Biochem; 2009 Jul; 107(4):769-84. PubMed ID: 19415685
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.
Watanabe K; Tominari T; Hirata M; Matsumoto C; Maruyama T; Murphy G; Nagase H; Miyaura C; Inada M
Biochem Biophys Res Commun; 2016 Sep; 478(1):154-161. PubMed ID: 27450806
[TBL] [Abstract][Full Text] [Related]
10. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
11. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
12. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Ye L; Lewis-Russell JM; Davies G; Sanders AJ; Kynaston H; Jiang WG
Int J Oncol; 2007 Feb; 30(2):521-9. PubMed ID: 17203235
[TBL] [Abstract][Full Text] [Related]
14. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of osteoblastic bone metastases from prostate cancer.
Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
17. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
[TBL] [Abstract][Full Text] [Related]
18. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
Straign DM; Ihle CL; Provera MD; Owens P
Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
[TBL] [Abstract][Full Text] [Related]
19. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
Ye L; Kynaston HG; Jiang WG
Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.
Chen WY; Liu SY; Chang YS; Yin JJ; Yeh HL; Mouhieddine TH; Hadadeh O; Abou-Kheir W; Liu YN
Oncotarget; 2015 Jan; 6(1):441-57. PubMed ID: 25436980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
